antibody-drug conjugates

Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd). Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.

Enfortumab vedotin-ejfv (Padcev) is an ADC compound targeting Nectin-4 with anti-tumor activity, used in the study of urothelial carcinoma.

Succinic anhydride is a cyclic anhydride. Succinic anhydride acts as a nonclaevable ADC linker. Succinic anhydride can react with compound 4 to link the prodrug to an amine or hydroxy 1 group of a targeting polypeptide.

Auristatin E, a cytotoxic tubulin modifier, disrupts cell division by inhibiting tubulin polymerisation. This compound demonstrates potent and selective antitumor activities, serving as an MMAE analog and cytotoxin in antibody-drug conjugates.

Fmoc-Val-Cit-PAB-PNP is a linker used in Antibody-Drug Conjugation (ADC).

Mc-Gly-Gly-Phe-Gly-PAB-OH, also known as Mc-GGFG-PAB-OH, is a cleavable ADC linker used specifically in the synthesis of antibody-drug conjugates (ADCs).

HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a peptide-cleavable agent-linker conjugate used in antibody-drug conjugates (ADCs), with DM indicating the maytansinoid component [1].